TAVNEOS Drug Patent Profile

Which patents cover Tavneos, and when can generic versions of Tavneos launch?

Tavneos is a drug marketed by Chemocentryx and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-two patent family members in thirty-nine countries.

The generic ingredient in TAVNEOS is avacopan. One supplier is listed for this compound. Additional details are available on the avacopan profile page.

DrugPatentWatch^® Generic Entry Outlook for Tavneos

Tavneos was eligible for patent challenges on October 7, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 27, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TAVNEOS

International Patents:	132
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	1
Patent Applications:	266
Drug Prices:	Drug price information for TAVNEOS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAVNEOS
What excipients (inactive ingredients) are in TAVNEOS?	TAVNEOS excipients list
DailyMed Link:	TAVNEOS at DailyMed

See drug prices for TAVNEOS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAVNEOS

Constraining patent/regulatory exclusivity:

11,951,214

NDA:

214487

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAVNEOS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Robert Spiera, MD	PHASE2
Amgen	PHASE2

See all TAVNEOS clinical trials

Pharmacology for TAVNEOS

Drug Class	Complement 5a Receptor Antagonist
Mechanism of Action	Complement 5a Receptor Antagonists Cytochrome P450 3A4 Inhibitors

Paragraph IV (Patent) Challenges for TAVNEOS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAVNEOS	Capsules	avacopan	10 mg	214487	3	2025-11-13

US Patents and Regulatory Information for TAVNEOS

TAVNEOS is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,951,214.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,603,356		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,445,515		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	11,951,214		Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes	8,906,938		Y	Y
Chemocentryx	TAVNEOS	avacopan	CAPSULE;ORAL	214487-001	Oct 7, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for TAVNEOS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vifor Fresenius Medical Care Renal Pharma France	Tavneos	avacopan	EMEA/H/C/005523Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Authorised	no	no	yes	2022-01-11

International Patents for TAVNEOS

When does loss-of-exclusivity occur for TAVNEOS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAVNEOS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020378397
Brazil	112022007489
Canada	3155542
Chile	2022001172
China	114641288

Supplementary Protection Certificates for TAVNEOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2381778	301166	Netherlands		PRODUCT NAME: AVACOPAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1605 20220119
3508477	PA2022006	Lithuania		PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111
2381778	2022C/518	Belgium		PRODUCT NAME: TAVNEOS - AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
2381778	LUC00258	Luxembourg		PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119
2381778	CA 2022 00022	Denmark		PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119

TAVNEOS (avacopan) Market Dynamics and Financial Trajectory: Exclusivity Timeline, Patent/Generic Risk, Pricing, Uptake, and Revenue Outlook

Last updated: July 21, 2026

Avacopan (TAVNEOS) is commercially scaling but remains exposed to a tight competitive window against established AAV- and steroid-based vasculitis standards. Near-term market dynamics hinge on (1) continued clinician adoption in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), (2) payer contracting and bundle economics tied to reduced corticosteroid exposure, and (3) manufacturing and channel execution for specialty distribution. Longer-term financial trajectory depends on the exclusivity and patent estate around formulation and use, plus whether biosimilar-like substitution is relevant (it is not, given avacopan is a small molecule), and whether generic entry pressures emerge when exclusivity/patents expire.

---

TAVNEOS (avacopan) Revenue trajectory: what does the financial path look like post-launch?

Bottom line: TAVNEOS revenue trajectory follows a typical specialty launch curve with uneven quarter-to-quarter performance driven by payer coverage, site-of-care patterns in AAV care, and uptake of guideline-concordant regimens. The commercial scaling profile is primarily a function of (a) number of eligible treated patients (new diagnoses plus switches from conventional steroids), (b) duration of avacopan courses in routine practice, and (c) net price after contracting and rebates.

What drives TAVNEOS sales volume in real-world AAV care?

Key volume drivers in ANCA-associated vasculitis include:

• Eligible patient mix: Patients with active AAV where clinicians seek steroid-sparing regimens.
• Treatment line positioning: First-line versus relapsed/refractory patterns, and preference versus cyclophosphamide/rituximab plus corticosteroids.
• Therapy duration adherence: Revenue is sensitive to actual course length versus trial durations due to payer restrictions and patient-specific discontinuation.
• Care setting: Specialty centers accelerate adoption. Community and non-specialty sites lag until formulary inclusion stabilizes.

What drives TAVNEOS net revenue per dose?

Net pricing reflects:

• Payer formulary position: Preferred specialty tier versus non-preferred status can materially impact volume.
• Rebate and outcomes arrangements: Where payers contract on steroid-sparing or hospitalization reduction logic.
• Dose intensity and administration constraints: If payers impose utilization management, actual average dose can drift.

---

How do payer coverage and contracting shape TAVNEOS market access and net pricing?

Bottom line: Market access is the single largest short-term determinant of TAVNEOS financial performance because AAV is niche, prescribing is concentrated, and payers often require documentation that steroid exposure is clinically constrained.

Common contracting levers that impact specialty small-molecule sales

• Prior authorization and step edits: Documentation of AAV diagnosis and treatment regimen.
• Centers of excellence or specialty pharmacy routing: Impacts turnaround times and adherence.
• Formulary exclusions: Competing steroid-sparing or steroid-sparing claims may shift access.
• Budget impact: Payers may treat avacopan cost against avoided steroid adverse events and related downstream costs.

What matters for contracting outcomes?

• Clinical differentiation narrative: Steroid reduction versus standard-of-care regimens.
• Real-world evidence pressure: Payers increasingly demand consistency between label positioning and clinical practice.

---

Who are TAVNEOS competitors in ANCA-associated vasculitis, and how does that affect pricing power?

Bottom line: TAVNEOS competes indirectly and directly for treatment intent with AAV regimens using corticosteroids plus immunosuppressants (cyclophosphamide, rituximab) and steroid taper strategies. This limits pure pricing power until avacopan becomes a “default” steroid-sparing option on payer formularies.

Competitive framework: where TAVNEOS competes

• Indication overlap: AAV treatment where corticosteroids are conventionally used.
• Treatment strategy competition: Steroid-sparing intent is the core commercial wedge.
• Institutional protocols: Many AAV centers have standardized steroid taper pathways. Changing protocols takes time.

Pricing implications of competitive positioning

• High payer friction reduces early pricing capture.
• If prescribers adopt avacopan as routine steroid-sparing backbone, net price stabilizes better.
• If adoption stays restricted to subgroups, volume grows slower and price face pressure via formulary leverage.

---

What patent estate protects TAVNEOS, and when does it lose exclusivity?

Bottom line: The timing for generic risk depends on (1) the U.S. Orange Book listing(s) and (2) the last expiring patent(s) covering avacopan composition, formulations, and method(s) of use. Generic and biosimilar risk is not symmetric. Avacopan is not eligible for biosimilar pathways because it is not a biologic, so “biosimilar risk” is not the relevant substitution channel. The relevant threat is small-molecule generic entry, possibly via Paragraph IV.

U.S. exclusivity categories that typically matter for brand small molecules

• Patent term (composition/formulation/method patents).
• Regulatory exclusivity: New Chemical Entity (NCE), if applicable, and other statutory exclusivities if triggered.
• Data exclusivity: Often shorter than patent term; does not prevent Paragraph IV.

Practical generic entry trigger for TAVNEOS

The “entry clock” is not a single date. Generic feasibility is a function of:

• the earliest patent expiration listed in Orange Book, and
• whether listed patents can be carved out or designed around,
• plus whether authorized generic or settlements deter entry.

---

What generic entry risks exist for TAVNEOS, including Paragraph IV litigation scenarios?

Bottom line: Generic entry risk exists primarily through Paragraph IV challenges after patent cliffs. The magnitude depends on whether the patent estate is dense, whether method-of-use claims are vulnerable, and whether settlements set earlier-than-expiry launch dates.

Paragraph IV pathways that change financial trajectory

• Single-patent challenge with narrow design-around can accelerate entry.
• Settlement agreements can shift entry timing via a negotiated “carve-out” date.
• Concurrent litigation can delay entry but does not eliminate longer-term pricing compression.

What to watch as market indicators

• Orange Book amendment activity (new patents listed or withdrawn).
• Generic filings that signal imminent Paragraph IV challenges.
• Court schedules and settlement press releases.

---

How strong is the patent estate for avacopan (TAVNEOS) across composition, formulation, and method-of-use?

Bottom line: Patent estate strength determines the duration of premium net pricing and the size of the price cliff. For specialty small molecules, the most durable protection often comes from composition-of-matter plus method-of-use or specific dosing regimens, supplemented by formulation patents that can block “easy” reformulations.

Patent estate dimensions that matter commercially

• Density of claims and number of listed patents: Higher density typically reduces generic design-around options.
• Breadth of method claims: Broad claims create higher litigation exposure for challengers.
• Formulation constraints: If patents lock specific excipients, release profiles, or stability-enhancing manufacturing features, generics face additional development work.

---

How does TAVNEOS compare with standard AAV steroid regimens in market adoption dynamics?

Bottom line: Commercial adoption follows clinicians’ willingness to switch from entrenched steroid taper frameworks. Where institutional protocols already incorporate steroid-sparing logic, avacopan adoption accelerates. Where protocols are conservative, it slows.

Adoption friction points

• Clinical workflow change: Protocol revisions and nurse/pharmacy training.
• Payer utilization management: Documentation burden and time-to-approval.
• Patient-specific contraindications and monitoring practices.

Adoption tailwind points

• Demonstrated steroid reduction value: If payers and clinicians accept steroid adverse-event risk tradeoffs, avacopan becomes a preferred regimen.
• Specialty center concentration: If early adopters standardize, the case volume concentrates.

---

What is the FDA regulatory and Orange Book status of TAVNEOS?

Bottom line: The FDA regulatory pathway influences how quickly the brand can build coverage and how payers interpret evidence. The Orange Book status determines patent-listed barriers to generic entry.

Regulatory status elements that affect commercialization

• Label positioning: Which patient subgroups are explicitly supported.
• Post-approval evidence cadence: Additional studies that expand use cases can improve volume.
• Safety monitoring requirements: If monitoring is burdensome, uptake can slow in community settings.

Orange Book status elements that affect litigation risk

• Listed patents and expiration schedule: Determines when Paragraph IV becomes available.
• Patent types: Composition, formulation, and method patents affect design-around strategies.

---

TAVNEOS launch strategy and manufacturing constraints: what could limit growth?

Bottom line: Growth is most vulnerable to specialty-channel constraints: fulfillment reliability, specialty pharmacy inventory management, and payer start-stop utilization management that can intermittently reduce continuity of dosing.

Manufacturing and supply considerations

• Batch release timelines and quality controls: Affect steady shipment.
• Capacity planning for dose demand: AAV is niche but concentrated in key centers; supply must match those demand clusters.

Channel execution risks

• Reimbursement delays: Can create backorders in patient starts.
• Coverage variability across regions: Leads to “patchy” adoption and uneven quarterly revenue.

---

Which companies are likely to compete or challenge TAVNEOS, and what does that imply for near-term revenue?

Bottom line: Generic challengers typically appear after patent cliffs. Near-term, competitive pressure is mostly from standard-of-care and contracting dynamics rather than immediate substitution. The financial sensitivity increases sharply around the first patent expiration windows.

Commercial implications of challenger behavior

• Early challenger visibility: Suggests future price pressure and may prompt payers to reprice coverage sooner.
• Settlement signals: If settlements cap entry at later dates, revenue can extend beyond initial market expectations.

---

Key financial sensitivity analysis for TAVNEOS: what moves revenue the most?

Bottom line: Revenue is most sensitive to (1) payer-covered patient starts, (2) net price after contracting, and (3) duration of use in routine AAV workflows.

Revenue levers

• Patient starts (volume): Controlled by formulary access and clinician adoption.
• Dose exposure (utilization): Controlled by regimen duration and treatment adherence.
• Net price (price): Controlled by rebates, utilization management, and coverage tiering.
• Competition intensity: Controlled by standard-of-care changes and any generic or authorized generic pressure.

---

Key Takeaways

• TAVNEOS revenue growth is primarily driven by specialty adoption in ANCA-associated vasculitis and payer contracting that supports steroid-sparing use.
• Market access friction from prior authorization and formulary tiering can dominate quarter-to-quarter revenue.
• Competitive pressure is currently more about standard-of-care steroid regimens and contracting strategy than immediate small-molecule substitution.
• Future pricing cliffs depend on the U.S. Orange Book patent and exclusivity schedule covering avacopan; Paragraph IV risk emerges when patent barriers reach their expiration windows.

---

FAQs

1. What drives TAVNEOS formulary inclusion and payer coverage decisions in ANCA-associated vasculitis?
2. How do Paragraph IV filings typically change the launch timing and settlement landscape for specialty small molecules like avacopan?
3. What patient subgroups most influence TAVNEOS uptake and persistence in real-world AAV treatment?
4. Does TAVNEOS face biosimilar competition, or is the substitution risk limited to small-molecule generics?
5. What manufacturing or specialty pharmacy factors most commonly delay TAVNEOS patient starts during scaling?

---

References

(No sources were provided in the prompt, and the response requires specific Orange Book, FDA, patent, and financial data that must be cited inline. Without sourced facts, a complete, citation-backed analysis cannot be produced.)

DrugChatter Q&A for TAVNEOS

Evaluate the biopharma company tavneos on autoimmune kidney disease therapy?
Evaluate the biopharma company tavneos on c5a receptor inhibitor?
Evaluate the biopharma company tavneos on oral complement pathway inhibitor?
What are the side effects of Tavneos?
Is Tavneos for Vasculitis?